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Abstract  
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a severely debilitating condition of multifactorial pathogenesis. It 
primarily involves patients receiving intravenous bisphosphonates (BPs) and most recently the new antiresorptive drug, denosumab, for 
the treatment of skeletal-related malignancies. There is no curative treatment and no consensus exists regarding the clinical management of 
such patients. This review aims to share our current clinical experience at Sheffield Teaching Hospitals’ Trust and raise awareness of the 
increase in severity of ONJ in patients receiving denosumab.  
Patients and Methods: Four new cases with clinical diagnosis of MRONJ were presented to Sheffield Teaching Hospitals’ Trust. MRONJ 
was attributed to denosumab therapy, as all patients were treated solely with denosumab for skeletal-related malignancies.  
Results: All cases appear to have a more aggressive mode of ONJ compared to that seen with IV and/or oral BPs so far. The cause of 
MRONJ was observed in the presence of periodontal disease alone and following dental extractions. Progression of the disease occurred 
considerably faster with the development of widespread suppuration and tooth mobility within weeks. Imaging revealed rather extensive 
areas of bony destruction, sometimes with associated periosteal reaction in keeping with a chronic bony infection.  
Conclusion: It is imperative for all dental and medical teams involved in treating these patients to understand the side effects of RANKL 
inhibitors on bone metabolism and how it affects treatment. Helping patients to understand the chronicity and potential progression of 
the disease is essential to a satisfactory outcome. 
Keywords: Osteonecrosis of the jaw, bisphosphonates, denosumab  
Abbreviations: MRONJ- Medication-related osteonecrosis of the jaw; BPs- Bisphosphonates; SREs- skeletal-related events; IV- 
intravenous; RANKL-Receptor activator of nuclear factor kappa-B ligand; MM- Multiple myeloma; ONJ- Osteonecrosis. 
 
Introduction 
Metastatic bone disease is a relatively common event in the 
advanced stages of many malignancies.1 Bone-modifying agents 
decrease the incidence of skeletal-related events (SREs) such as 
spinal cord compression and bone fracture, as well as the need 
for skeletal radiotherapy or surgery.2 
Bone modifying agents such as intravenous bisphosphonates 
(IV BPs) (e.g. pamidronate and zoledronic acid) and 
denosumab are approved for prevention of SREs. IV BPs are 
primarily used and effective in the treatment and management 
of cancer related conditions such as multiple myeloma (MM), 
and breast cancer with skeletal metastases, because they reduce 
bone pain, hypercalcemia, and the risk of pathologic fractures.3 
Denosumab, a receptor activator of nuclear factor kappa-B 
ligand (RANKL) inhibitor, represents a breakthrough in the 
treatment of osteoporosis, MM, and bone metastases. The Food 
and Drug Administration (FDA) approved it in 2010 for the 
prevention of SREs in patients with bone metastases and in 
2011 for the prevention of endocrine-therapy induced bone loss 
in patients taking aromatase inhibitors for breast cancer and in 
patients with non-metastatic prostate cancer. 
Three international, randomised, double-blind, double-dummy 
phase III studies have evaluated denosumab versus zoledronic 
acid for the treatment of SREs in breast and prostate cancers, 
and in combined solid tumours and MM. Denosumab’s 
superior efficacy over zoledronic acid was demonstrated in the 
studies of patients with advanced breast or prostate cancer, as 
well as in a pre-specified integrated analysis of all patients 
enrolled across the three studies.4 
In the 2014 position paper of the American Association of Oral 
and Maxillofacial Surgeons (AAOMS), the nomenclature 
“bisphosphonate-related osteonecrosis of the jaw” changed to 
“medication related osteonecrosis of the jaw” (MRONJ). 
MRONJ is defined as cases in which all of the following 3 
characteristics are present5: 
 current or previous treatment with antiresorptive or 
antiangiogenic agents 
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 exposed bone or bone that can be probed through an 
intraoral or extra-oral fistula in the maxillofacial region 
that has persisted for longer than 8 weeks 
 no history of radiation therapy to the jaws or obvious 
metastatic disease to the jaws 
Other terminologies used previously include “denosumab 
related osteonecrosis of the jaw” (DRONJ), and “antiresorptive 
agent-induced ONJ” (ARONJ). 
The aetiopathogenesis of MRONJ related to denosumab 
therapy remains enigmatic, and hypotheses have focused on 
reduced bony turnover, infection, toxicity of the soft tissue, and 
antiangiogenesis. The epidemiology also remains unclear, and 
reported incidence varies widely.6 Overall, it is estimated that 
bone necrosis can develop in about 0.7-1.9% of patients with 
malignancy who are given high-potency IV BPs (such as 
zoledronic acid), and in 0.01–0.1% of those with osteoporosis 
who take low-potency oral BPs (such as alendronate). Data 
relevant to denosumab given subcutaneously in patients with 
metastatic cancer and osteoporosis seem to replicate those when 
IV high-potency BPs are administered.7 The risk of 
osteonecrosis of the jaw (ONJ) is higher in patients exposed to 
concomitant antiagiogenic medication. The individuals’ risk of 
ONJ is further determined by factors such as the potency of 
agent, cumulative dosage or duration of antiresorptive 
treatment, route of administration, comorbidities and local 
factors such as periodontal disease.8,9 Oral hygiene plays a 
significant role with evidence supporting a strong correlation 
between bacteria associated with periodontal disease and 
MRONJ.10 
MRONJ typically manifests as painful and often infected areas 
of necrotic bone, which subsequently may lead to severe chronic 
pain and facial disfigurement. This adversely affects the ability 
to eat, speak and lowers the quality of life. Adverse events 
related to RANKL inhibitors are usually considered to be 
infrequent and low in occurrence. Unfortunately from our 
recent clinical experience at Sheffield Teaching Hospitals' 
Trust, there have been several new cases presented in a very 
short period of time. In this paper we present a case series of 
MRONJ related to denosumab therapy since adverse events of 
denosumab in the mandible or maxilla have received relatively 
little attention. 
The aim of this article is to highlight the elevated risk of 
MRONJ in patients receiving denosumab treatment and 
educate all health care providers involved in the management of 
such patients. Furthermore, the mechanisms of denosumab, 
comparison with bisphosphonates and the reported 
management strategies are reviewed. 
Mechanism of Denosumab 
Denosumab is an antiresorptive agent that exists as a human 
IgG2 monoclonal antibody and inhibits the binding of the 
receptor activator of nuclear factor kappa-B ligand (RANKL) to 
RANK (Receptor Activator of Nuclear Factor kappa-B). The 
binding normally signals the proliferation of osteoclasts, as 
RANK is expressed on the surface of osteoclasts and their 
precursors, whereas its ligand, RANKL, is a membrane bound 
protein expressed by bone marrow stromal cells, osteoblasts and 
T-lymphocytes. The activation of RANK is integral to the 
function of osteoclasts. Osteoprotegerin binds to membrane 
bound RANKL on osteoblast which in turns decreases the 
osteoclastic activity and in theory negatively effects bone 
turnover. Denosumab acts similarly to osteoprotegerin but has a 
higher affinity for RANKL.11-13 
Denosumab follows nonlinear, dose-dependent 
pharmacokinetics. The bioavailability of one subcutaneous 
denosumab injection is 61% and serum concentrations are 
detected within 1 hour. Maximum serum concentrations occur 
in 5-21 days and cessation of osteoclast activity occurs within 
six hours of the subcutaneous injection. The normal function is 
restored approximately six to nine months later, whilst bone 
turnover returns to normal shortly after this.14 Based upon 
monoclonal antibody pharmacokinetics, denosumab is most 
likely cleared by the reticuloendothelial system with minimal 
renal filtration and excretion thus avoiding nephrotoxicity. Its 
elimination half-life is 32 days, and it does not incorporate into 
bone.15 
It is currently marketed as Prolia® and Xgeva®, approved by 
FDA. Prolia® is administered subcutaneously every six months 
and has shown to reduce the incidence of new vertebral, non-
vertebral, and hip fractures in osteoporotic patients.16,17 Xgeva® 
is also effective in reducing SRE related to metastatic bone 
disease from solid tumours when administered intravenously on 
a monthly basis.17,18 
RANKL Inhibitors and BPs Pharmacokinetics 
There are fundamental differences between denosumab and BPs 
with regard to their mode of action. Denosumab is an antibody 
and acts extracellularly whereas BPs act intracellularly. As such, 
BPs must be present in the circulation and available for 
reuptake into bone for prolonged periods to function.19 There is 
not any evidence of drug recycling with RANKL inhibitors, and 
therefore it is suggested that their adverse effects can be 
reversible with discontinuation, in fact leading to a transient 
rebound phenomenon, which can be restored, with subsequent 
treatment.14,20 On the other hand, recycling of BPs in the 
circulation system has been proposed as a reason for the long 
duration of action even after cessation which can be up to 12 
years. 
The US FDA-approved manufacturer’s package insert for both 
zolendronate and pamidronate states that “there are no data 
available to suggest whether discontinuation of bisphosphonate 
treatment reduces the risk of ONJ in patients who require 
dental procedures during therapy and that clinical judgment of 
the treating physician should guide the management plan of 
each patient based on individual benefit/ risk assessment”. The 
package insert for denosumab does not address the issue of 
treatment continuation in patients who develop MRONJ to 
date. 
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Denosumab is a circulating protein capable of distributing 
throughout extravascular space. It is expected to reach all sites 
within bone including intracortical sites unlike with BPs. BPs 
have strong affinity for hydroxyapatite and bone mineral which 
limits their even distribution throughout the skeleton, 
particularly to sites deep within the bone.19,21 This can explain 
the more profound inhibition of bone remodelling with 
denosumab than that seen with BPs. 
Case Series 
Case 1 
A 55 year-old lady referred to a dedicated Oral Surgery nerve 
injury clinic for an opinion and management of her left sided 
inferior alveolar nerve (IAN) paraesthesia. The patient 
presented with a history of numbness in the left sided inferior 
alveolar nerve distribution following removal of the left 
mandibular second premolar (LL5) in July 2014. She was 
asymptomatic until she had the LL5 removed and since had 
suffered with constant pain and numbness. A year later, she had 
removal of the left mandibular first molar (LL6) and gave a 
history of recurrent infections and excruciating pain in her 
mandible over the past two months. On presentation she had 
an obvious submental swelling and left sided IAN anaesthesia. 
Medically she was diagnosed with breast cancer in 2011, for 
which she underwent wide local excision followed by 
chemotherapy. She then was placed on unknown clinical trial 
that we identified at the time to be denosumab trial, following 
liaison with the Oncology team. She is currently receiving 
intravenous denosumab every three months. 
Clinical examination revealed a grossly mobile anterior 
mandible with widespread bony necrosis and associated 
osteomyelitis. Sensory testing revealed complete anaesthesia in 
the left sided IAN distribution secondary to MRONJ. 
An OPG (Orthopantogram) and CBCT (Cone-Beam 
Computerised Tomography) revealed an extensive patchy area 
of ill-defined bone loss in the anterior mandible extending 
posteriorly to the premolar/molar areas bilaterally (Fig 1). 
 
Figure 1 A) OPG showing non-healing sockets in the left 
mandible with extensive bony destruction together with 
periosteal reaction extending to the right mandible as shown by 
the arrows. 
Rather interestingly, the bony destruction was evident 
bilaterally with the patient only having had extraction of teeth 
in the left mandible (Fig 1). This could be the case of 
spontaneous ONJ in the right mandible or an extensive ONJ 
arising from simple extractions on the left side. 
 
Figure 2 3D reconstruction of the CBCT image demonstrating 
extensive bony destruction involving the lower border of 
anterior mandible in keeping with a spreading chronic bony 
infection and clinical presentation of submental swelling as 
showing by arrows. 
Case 2 
A 66-year-old female referred by her general medical 
practitioner (GMP) with a 3-month history of delayed healing 
following a tooth extraction in the left posterior mandible. She 
had moderate to severe discomfort and reported multiple 
previous infections and purulent discharge from the area, which 
treated with multiple courses of antibiotics. In addition, she 
reported discomfort from the root treated right mandibular first 
and second premolar teeth (LR4 and LR5). 
Medically she was diagnosed with breast cancer over 10 years 
ago for which she underwent resection followed by 
chemotherapy. Three years ago, she diagnosed with metastatic 
deposits and therefore has been receiving intravenous 
denosumab every six weeks since then. Other medications 
include steroids, chemotherapy agents, antihypertensives and 
analgesics. She did not receive any radiotherapy or BPs 
treatment in the past. 
Clinical presentation revealed a heavily restored dentition with 
chronic generalised periodontal disease. There was evidence of 
widespread bone loss clinically and radiographically. The slow 
healing socket in the left mandible was visible but did not have 
any exposed bone (Fig 3). The lower right first and second 
premolar teeth (LR4 and LR5) were clinically and 
radiographically sound. 
British Journal of Medical Practitioners, December 2016, Volume 9, Number 4 
 
BJMP.org 
 
Figure 3. Non-healing socket in the left posterior mandible 
with no evidence of exposed bone or suppuration as showing by 
white arrow. Gingiva recession (black arrows) is evident in the 
LL6 and LL5 teeth in keeping with chronic periodontal disease. 
 
Figure 4 Coronal sections of CBCT A and B showing multiple 
lytic areas within the inferior cortex of the mandible and 
incomplete healing of the extraction sockets. 
On follow-up appointments, the patient suffered multiple 
repeated infections in the right and left posterior mandible and 
due to deteriorating periodontal disease, the LR4, LR5, LR6 
were extracted by her own general dental practitioner (GDP) 
due to severe mobility. All three extraction sockets failed to heal 
(Fig 5) leading to an extensive area of exposed bone in the right 
mandible, extending from the lower right first premolar (LR4) 
to lower left first molar (LL6) region. Conservative 
management was embarked which included antibiotics, 
chlorhexidine mouthwash and routine oral hygiene 
appointments. Selective sharp bone trimming and three 
sequestrectomies were undertaken. At the same time, liaison 
with the patient’s oncologist resulted in cessation of the 
denosumab therapy and complete resolution of her oral 
symptoms. 
 
Figure 5 Clinical picture of exposed necrotic bone (white 
arrows) following simple extractions of periodontally involved 
teeth. 
Case 3 
A 76-year-old lady referred to the Oral Surgery department by 
her GDP with a 3-month history of a non-healing lower left 
first premolar (LL4) socket. The patient was treated with two 
courses of antibiotics prior to referral which provided only 
temporary relief to her symptoms. 
Medically she was diagnosed with breast cancer 10 years ago 
and recently commenced intravenous denosumab for metastatic 
disease. She also receives hormone therapy and palliative 
radiotherapy to the spine. 
On clinical examination, there was a partially healed LL4 socket 
with a rather granulomatous appearance. There was no clinical 
evidence of suppuration or bony exposure. Radiographs 
confirmed the absence of bony infill in the socket. Local 
debridement and biopsy of the granulomatous tissue was 
performed to exclude any metastatic disease. Biopsy report 
confirmed the presence of inflammation tissue. 
 
Figure 6 CBCT scan; A and B sagittal views, C axial view and 
D 3D reconstruction. Extensive periosteal reaction extending 
from the midline of the mandible to the left molar region is 
evident in keeping with chronic osteomyelitis secondary to 
MRONJ. 
Liaison with the microbiologist suggested a long-term antibiotic 
course to arrest osteomyelitis. Further liaison with the oncology 
team, resulted in denosumab being stopped for 4 months. On 
subsequent review appointments, patient’s symptoms improved 
however, there is now an area of exposed bone in the LL4 
region as shown in Fig 7. 
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Figure 7 Clinical photo illustrating exposed bone (white arrow) 
in the LL4 region without evidence of local infection. 
Case 4 
A 65-year-old lady referred to the Oral Surgery department by 
her GDP with a history of a sore upper mouth and jaw 
underneath the dentures which is unable to wear. 
Medically she was diagnosed with disseminated breast 
malignancy including bone metastases 3 years ago and for that, 
she is on exemestane and IV Denosumab monthly. 
Clinical examination revealed multiple draining sinuses in the 
anterior maxilla. There was a partially healed LL4 socket with a 
rather granulomatous appearance and tenderness on palpation. 
There was neither discharge from the area nor any exposed 
bone. Radiographs confirmed the absence of bony infill in the 
LL4 socket. Local debridement and biopsy of the 
granulomatous tissue was performed to exclude any potential 
malignancy and it was confirmed as inflammation tissue. 
 
Figure 8 CBCT scan; A axial view, B and C 3D reconstruction. 
A 25mm fragment of right anterior maxilla is beginning to 
sequestrate. This extends from the anterior margin of the right 
maxillary sinus approximately to the position of the upper left 
lateral incisor, crossing the midline. The sequestrated fragment 
involves the lateral margin of the nasal cavity. There is bilateral 
moderate mucosal thickening in the maxillary sinuses. Extensive 
periosteal reaction extending from the midline of the mandible 
to the left molar region is evident in keeping with chronic 
osteomyelitis secondary to MRONJ. 
Table 1 Summary of cases 
Cases Indications Duration 
(months) 
Clinical Findings 
Case 
1 
Metastatic deposits 
from primary breast 
malignancy 
48 Anaesthesia in the 
distribution of the left 
inferior alveolar nerve 
Osteomyelitis 
Excruciating pain 
Case 
2 
Metastatic deposits 
from primary breast 
malignancy 
36 Chronic generalised 
adult periodontal 
disease 
Non-healing 
extraction sockets 
Exposed bone 
persisted for longer 
than 8 weeks 
Severe pain 
Case 
3 
Metastatic deposits 
from primary breast 
malignancy and 
myeloma 
24 Non-healing 
extraction socket with 
granulomatous tissue 
Severe pain 
Case 
4 
Disseminated breast 
malignancy including 
bone metastases 
30 Multiple draining 
sinuses in anterior 
maxilla 
Non-healing 
extraction socket with 
granulomatous tissue 
Severe pain 
 
Discussion 
ONJ associated with antiresorptive therapy deserves distinction 
from other causes and diseases/medications associated with the 
development of osteonecrosis of the jaw. AAOMS recently 
published stage specific treatment recommendation for 
MORNJ.22 The various stages and suggested stage-specific 
treatment strategies are not evidence-based, and in particular, 
stage 0 disease is not universally accepted. AAOMS 
recommendations echoed those stated in previous years for 
BRONJ, namely supporting conservative therapy, with 
aggressive surgery offered only to symptomatic patients. In 
contrast, the MRONJ guideline report from the German 
Dental and the German Oral and Maxillofacial Associations 
refrains from recommending therapy at least for certain stages 
of the disease. This might be attributed to the pitfalls of current 
MRONJ criteria. Furthermore, due to poor guidelines 
specifically related to RANKL inhibitors, no agreement exists 
on a universally acceptable therapy strategy of such cases. 
Management strategies are largely based on expert opinion 
rather than experimental data. It includes prevention, 
conservative and surgical modalities. Prevention of the 
condition is the gold standard. It is highly recommended all 
patients have a comprehensive dental examination and 
preventive dentistry (pre-emptive extraction of unsalvageable 
teeth and optimised periodontal health) before commencing 
antiresorptive therapy.23,24 Oral hygiene should be kept 
meticulous during the course of therapy as periodontal disease 
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and associated bacteria claim to be implicated in this condition 
and also observed in these cases. 
The success rate of conservative treatment regimens range from 
less than 20% 25,26 to above 50%27,28 although some cases 
become chronic and develop complications.29 
Microbial cultures from areas of exposed bone are not always 
helpful since normal oral microbes are isolated. However, when 
there is extensive soft tissue involvement, microbial cultures 
may help to define comorbid oral infections, which may guide 
the selection of an appropriate antibiotic regimen.30 
Regardless of the stage of disease, areas of necrotic bone that are 
a source of chronic soft tissue irritation and loose bony 
sequestra should be removed or recontoured so that soft tissue 
healing can be optimised. This is in line with our clinical 
experience. The extraction of symptomatic teeth within 
exposed, necrotic bone should be considered as it appears 
unlikely that extraction will worsen the established necrotic 
process. Otherwise, surgical resection of necrotic bone should 
generally be reserved for refractory or advanced 
cases.31 Resection may occasionally result in even larger areas of 
exposed and painful infected bone.32 
A recently published MISSION study7 reported that the 
AAOMS system misclassified/ underestimated the severity of 
the disease at a rate of about 1 in 3, in particular in patients 
suffering from MRONJ stage 1 and 2. The authors conclude 
that these findings may explain why the treatment of stage 3 
ONJ, namely surgery with success rate over 85%33,34, has been 
deemed to be more predictable and therefore yields more 
favourable outcomes than the treatment of stages 1 and 2.35 
Denosumab is characterised by reversibility of its effect after 
treatment discontinuation, in contrast with bisphosphonates. 
This is in line with our findings since cessation of denosumab 
in two cases helped to improve their symptoms significantly. 
MRONJ has been reported to occur after a mean 
administration period of 39.3 months and 35 infusions in 
oncology patients.23 It is interesting that all published cases of 
denosumab-related ONJ occurred early after commencement of 
therapy, independent of the number of previous 
administrations.36,37 In our experience, all patients developed 
MRONJ within the first 3 months of teeth extractions; well 
ahead of the reported period and number of administrations of 
denosumab. 
Furthermore, all four cases have had extensive lytic lesions 
developed following removal of a single tooth. The common 
radiographic findings in all cases include: 
 non-healing extraction socket 
 areas of focal and diffuse sclerosis 
 thickened lamina dura 
 early sequestrum formation 
 reactive periosteal bone 
 osteolysis of cortical and spongious bone 
 
These findings, although common in MRONJ cases, have had 
extensive bony involvement and rapid progression of ONJ, 
demonstrating a far more aggressive nature of the disease 
compared to that seen with BPs. 
In our experience, not all patients are adequately informed of 
the risks and adverse events of denosumab therapy. This 
highlights the importance of educating patients and inter-
professional communication regarding the prevention and best 
management of MRONJ cases. In one of the cases, the lack of 
patient education concerning denosumab side effects and the 
failure of inter-professional communication had a detrimental 
effect on the patient’s overall management and subsequently 
patient’s oral health. 
Table 2 Important Points 
 All patients prior to start of any antiresorptive medication should 
have a dental check-up and receive dental or surgical treatment 
beforehand to avoid the possibility of complications associated with 
antiresorptive medications 
 Strongly recommend regular dental check-ups to prevent   
o Periodontal disease – dental caries – surgical treatment 
 Avoid surgical treatment where possible 
 Use of chlorhexidine mouthwash 
 Liaison between professions 
 Patients should be advised to contact their Doctor/Dentist/Oral 
surgeon immediately if notice following symptoms: 
o Feeling of numbness, heaviness or other unusual sensation in 
the jaw 
o Pain in the jaw / toothache 
o Delayed healing to the gums, especially after dental work 
o Bad taste / infection 
o Swelling of the jaw 
o Loose teeth 
o Exposed bone 
o Pus like discharge from the affected area 
 
Conclusion 
We present our experience with denosumab-related ONJ from 
Sheffield Teaching Hospital’s NHS Trust. This case series 
should contribute to the existing sparse clinical literature on this 
topic. The pathogenesis, treatment and outcome of ONJ are 
complex and multifactorial. Patients treated with denosumab 
may be more prone to developing ONJ even without a 
precipitating dental event. ONJ may have a more aggressive 
profile and develop significantly earlier in patients receiving 
denosumab. Prevention of ONJ still remains the most 
important goal, and this is most directly accomplished by 
avoiding invasive dental procedures and establishing inter-
professional communication. 
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